Clinical report. Pyoderma gangrenosum and cytokine elevation associated with work-related injury

1. Wollina U. Pyoderma gangrenosum - a review. Orphanet J Rare Dis. 2007; 15:2-19.10.1186/1750-1172-2-19185770417433111Search in Google Scholar

2. Ikeda K, Hamada T, Otsuka M, Iwatsuki K. Beneficial effects of neutrophil-targeted therapy for Pyoderma granulosum associated with ulcerative colitis. Eur J Dermatol. 2011; 9:804-5.Search in Google Scholar

3. Finkel SI, Janowitz HD. Trauma and the pyoderma gangrenosum of inflammatory bowel disease. Gut. 1981; 22:410-2.10.1136/gut.22.5.41014192377250753Open DOISearch in Google Scholar

4. Inan I, Myers PO, Braun R, Hagen ME, Morel P. Pyoderma gangrenosum after totally implanted central venous access device insertion. World J Surgical Oncol. 2008; 6:31-6.10.1186/1477-7819-6-31227082418325095Open DOISearch in Google Scholar

5. Noblette SE, Woodcock S. Port-site pyoderma gangrenosum - a rare condition of surgical trauma. Ann R Coll Surg Engl. 2009; 91:665-6.10.1308/rcsann.2009.91.8.665Open DOISearch in Google Scholar

6. Kawakami T, Yamakazi M, Soma Y. Reduction of interleukin-6, anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis. Am J Gastroenterol. 2009; 104:2363-4.10.1038/ajg.2009.27119727102Open DOISearch in Google Scholar

7. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010; 62:646-54.10.1016/j.jaad.2009.05.03020227580Open DOISearch in Google Scholar

8. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Prac Rheumatol. 2006; 2:619-26.10.1038/ncprheum033817075601Open DOISearch in Google Scholar

9. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006; 8:S3. Atreya R, Mudter J, Finotto S, M llberg J, Jostock T, Wirtz S, et al. Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn’s disease and experimental colitis in vivo. Nat Med. 2000; 6: 583-8.10.1038/7506810802717Search in Google Scholar

10. Panopoulos AD, Watowich SS. Granulocyte colonystimulating factor: Molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis. Cytokine. 2008; 42:277-88.10.1016/j.cyto.2008.03.002285242818400509Open DOISearch in Google Scholar

11. Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009; 5: 554-9.10.1038/nrrheum.2009.17819798030Open DOISearch in Google Scholar

12. Miall FM, Harman K, Kennedy B, Dyer MJ. Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma. Br J Haematol. 2005; 132:114-7.Search in Google Scholar

13. White LE, Villa MT, Petronic-Rosic V, Jiang J, Medenica MM. Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor. Skinmed. 2006; 5:96-8.10.1111/j.1540-9740.2006.04575.x16603845Open DOISearch in Google Scholar

14. Atreya R, Mudter J, Finotto S, M llberg J, Jostock T, Wirtz S, et al. Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn’s disease and experimental colitis in vivo. Nat Med. 2000; 6:583-8.10.1038/7506810802717Search in Google Scholar

15. Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, et al. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest. 2000; 80:595-604.10.1038/labinvest.378006410780675Search in Google Scholar